Cargando…

Heterogeneous Vancomycin Intermediate Staphylococcus aureus Infections in Diabetic and Non-Diabetic Patients – A Hospital-Based Comparative Study

PURPOSE: To study the infections caused by methicillin resistant Staphylococcus aureus (MRSA) with emphasis on heterogeneous vancomycin intermediate S. aureus (hVISA) in diabetic and non-diabetic patients and their comparison. PATIENTS AND METHODS: S. aureus strains isolated from diabetic and non-di...

Descripción completa

Detalles Bibliográficos
Autores principales:	M, Sreejisha, Mulki, Shalini Shenoy, Shenoy, Suchitra, Dhanashree, Biranthabail, M, Chakrapani, Bhat, Gopalakrishna
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Dove 2023
Materias:	Original Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9830051/ https://www.ncbi.nlm.nih.gov/pubmed/36636375 http://dx.doi.org/10.2147/IDR.S393415

Ejemplares similares

Draft Genome Sequences of Vancomycin-Susceptible Staphylococcus aureus Related to Heterogeneous Vancomycin-Intermediate S. aureus
por: Ramaraj, Thiruvarangan, et al.
Publicado: (2014)

Systematic Review and Meta-Analysis of the Epidemiology of Vancomycin-Intermediate and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolates
por: Zhang, Shanshan, et al.
Publicado: (2015)

Resistance and Molecular Characteristics of Methicillin-Resistant Staphylococcus aureus and Heterogeneous Vancomycin-Intermediate Staphylococcus aureus
por: Liang, Jin, et al.
Publicado: (2023)

Cell wall thickness and the molecular mechanism of heterogeneous vancomycin‐intermediate Staphylococcus aureus
por: Cui, J., et al.
Publicado: (2021)

Vancomycin (VAN) Combinations with Β-Lactams (BLs) against Methicillin-Resistant Staphylococcus aureus (MRSA), Heterogeneous Intermediate-Level Resistance to Vancomycin (hVISA) and Vancomycin-Intermediate Staphylococcus aureus (VISA)
por: Tran, Kieu-Nhi, et al.
Publicado: (2017)

Global prevalence and distribution of vancomycin resistant, vancomycin intermediate and heterogeneously vancomycin intermediate Staphylococcus aureus clinical isolates: a systematic review and meta-analysis
por: Shariati, Aref, et al.
Publicado: (2020)

Comparative Analysis of Virulence and Toxin Expression of Vancomycin-Intermediate and Vancomycin-Sensitive Staphylococcus aureus Strains
por: Jin, Ye, et al.
Publicado: (2020)

Molecular Events for Promotion of Vancomycin Resistance in Vancomycin Intermediate Staphylococcus aureus
por: Hu, Qiwen, et al.
Publicado: (2016)

Characterization of Infections with Vancomycin-Intermediate Staphylococcus aureus (VISA) and Staphylococcus aureus with Reduced Vancomycin Susceptibility in South Korea
por: Park, Jung Wan, et al.
Publicado: (2019)

Emergence of Vancomycin-Intermediate Staphylococcus aureus and S. sciuri, Greece
por: Tsakris, Athanassios, et al.
Publicado: (2002)

Molecular features of heterogeneous vancomycin-intermediate Staphylococcus aureus strains isolated from bacteremic patients
por: Maor, Yasmin, et al.
Publicado: (2009)

Prevalence and Clinical Impact of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Isolated From Hospitalized Patients
por: Koh, Young Rae, et al.
Publicado: (2016)

Detection of heterogeneous vancomycin-intermediate Staphylococcus aureus: A preliminary report from south India
por: Amberpet, Rajesh, et al.
Publicado: (2019)

Reconstruction of the Vancomycin-Susceptible Staphylococcus aureus Phenotype From a Vancomycin-Intermediate S. aureus XN108
por: Peng, Huagang, et al.
Publicado: (2018)

Complete Reconstitution of the Vancomycin-Intermediate Staphylococcus aureus Phenotype of Strain Mu50 in Vancomycin-Susceptible S. aureus
por: Katayama, Yuki, et al.
Publicado: (2016)

Molecular epidemiology of heteroresistant vancomycin-intermediate Staphylococcus aureus in Brazil
por: Silveira, Alessandro Conrado de Oliveira, et al.
Publicado: (2015)

Chemoproteomics of an Indole-Based Quinone Epoxide Identifies Druggable Vulnerabilities in Vancomycin-Resistant Staphylococcus aureus
por: Kulkarni, Amogh, et al.
Publicado: (2019)

Novel single-nucleotide variations associated with vancomycin resistance in vancomycin-intermediate Staphylococcus aureus
por: Lin, Lee-Chung, et al.
Publicado: (2018)

Fecal Carriage of Extended-spectrum Beta-lactamase-producing Enterobacteriaceae in Intensive Care Unit Patients
por: Mulki, Shalini Shenoy, et al.
Publicado: (2017)

Vancomycin-intermediate Staphylococcus aureus in a home health-care patient.
por: Hageman, J C, et al.
Publicado: (2001)

Comparative Proteomics-Based Identification of Genes Associated with Glycopeptide Resistance in Clinically Derived Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Strains
por: Chen, Hongbin, et al.
Publicado: (2013)

In vitro activity of recombinant lysostaphin in combination with linezolid, vancomycin and oxacillin against methicillin-resistant Staphylococcus aureus
por: Narasimhaswamy, Nagalakshmi, et al.
Publicado: (2017)

Draft Genomes of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus Strain MM66 and MM66 Derivatives with Altered Vancomycin Resistance Levels
por: Matyi, Stephanie A., et al.
Publicado: (2014)

Combination of cephalosporins with vancomycin or teicoplanin enhances antibacterial effect of glycopeptides against heterogeneous vancomycin-intermediate Staphylococcus aureus (hVISA) and VISA
por: Lai, Chih-Cheng, et al.
Publicado: (2017)

Novel Mutation Sites in the Development of Vancomycin- Intermediate Resistance in Staphylococcus aureus
por: Wang, Yubing, et al.
Publicado: (2017)

Effect of genetic background on the evolution of Vancomycin-Intermediate Staphylococcus aureus (VISA)
por: Su, Michelle, et al.
Publicado: (2021)

Clinical outcomes and molecular typing of heterogenous vancomycin-intermediate Staphylococcus aureus bacteremia in patients in intensive care units
por: Hu, Han-Chung, et al.
Publicado: (2015)

1249. Metabolomic Profile of Heterogeneous Vancomycin-Intermediate Staphylococcus aureus (hVISA) in Latin-American MRSA Isolates
por: Castro-Cardozo, Betsy E, et al.
Publicado: (2021)

The Role of β-Glycosylated Wall Teichoic Acids in the Reduction of Vancomycin Susceptibility in Vancomycin-Intermediate Staphylococcus aureus
por: Hort, Michael, et al.
Publicado: (2021)

Synergy of Arbekacin-based Combinations Against Vancomycin Hetero-intermediate Staphylococcus aureus
por: Lee, Ji-Young, et al.
Publicado: (2006)

Dissecting Vancomycin-Intermediate Resistance in Staphylococcus aureus Using Genome-Wide Association
por: Alam, Md Tauqeer, et al.
Publicado: (2014)

In vitro selection of Staphylococcus aureus mutants resistant to tigecycline with intermediate susceptibility to vancomycin
por: Herrera, Melina, et al.
Publicado: (2016)

Draft Genome Sequences of Vancomycin-Intermediate Staphylococcus aureus Strains in South Korea
por: Kim, Jung Wook, et al.
Publicado: (2016)

Apt (Adenine Phosphoribosyltransferase) Mutation in Laboratory-Selected Vancomycin-Intermediate Staphylococcus aureus
por: Lamichhane-Khadka, Reena, et al.
Publicado: (2021)

Cervimycin-Resistant Staphylococcus aureus Strains Display Vancomycin-Intermediate Resistant Phenotypes
por: Dietrich, Alina, et al.
Publicado: (2022)

Identification of Lysine Succinylome and Acetylome in the Vancomycin-Intermediate Staphylococcus aureus XN108
por: Tan, Li, et al.
Publicado: (2022)

Changing antibiotic susceptibility pattern in uropathogenic Escherichia coli over a period of 5 years in a tertiary care center
por: Prasada, Shobha, et al.
Publicado: (2019)

Fungal infections of spine: Case series during the COVID times
por: Keerthi C, Ishwara, et al.
Publicado: (2022)

Characterization of virulence factors and antibiotic resistance pattern of uropathogenic Escherichia coli strains in a tertiary care center
por: Kumar M, Naveen, et al.
Publicado: (2022)

Vancomycin Resistance in Staphylococcus aureus 
por: McGuinness, Will A., et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_ifij6j0pj286bfp1m7j9oovt3q